Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

MLA

Boni, C., et al. “Lamivudine Treatment Can Overcome Cytotoxic T-Cell Hyporesponsiveness in Chronic Hepatitis B: New Perspectives for Immune Therapy.” Hepatology (Baltimore, Md.), vol. 33, no. 4, Apr. 2001, pp. 963–71. EBSCOhost, https://doi.org/10.1053/jhep.2001.23045.

APA

Boni, C., Penna, A., Ogg, G. S., Bertoletti, A., Pilli, M., Cavallo, C., Cavalli, A., Urbani, S., Boehme, R., Panebianco, R., Fiaccadori, F., & Ferrari, C. (2001). Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology (Baltimore, Md.), 33(4), 963–971. https://doi.org/10.1053/jhep.2001.23045

Chicago

Boni, C, A Penna, G S Ogg, A Bertoletti, M Pilli, C Cavallo, A Cavalli, et al. 2001. “Lamivudine Treatment Can Overcome Cytotoxic T-Cell Hyporesponsiveness in Chronic Hepatitis B: New Perspectives for Immune Therapy.” Hepatology (Baltimore, Md.) 33 (4): 963–71. doi:10.1053/jhep.2001.23045.